S Albánez1, K Ogiwara1, A Michels1, W Hopman2, J Grabell3, P James3, D Lillicrap1. 1. Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada. 2. Department of Public Health Sciences, Queen's University, Kingston, ON, Canada. 3. Department of Medicine, Queen's University, Kingston, ON, Canada.
Abstract
UNLABELLED: Essentials von Willebrand factor (VWF) and factor VIII (FVIII) levels are modulated by age and ABO status. The effect of aging and ABO blood type on VWF and FVIII was assessed in 207 normal individuals. Aging and ABO blood type showed combined and bidirectional influences on VWF and FVIII levels. Aging and ABO blood type influence VWF levels through both secretion and clearance mechanisms. SUMMARY: Background The effect of aging and ABO blood type on plasma levels of von Willebrand factor (VWF) and factor VIII (FVIII) have been widely reported; however, a comprehensive analysis of their combined effect has not been performed and the mechanisms responsible for the age-related changes have not been determined. Objectives To assess the influence of aging and ABO blood type on VWF and FVIII levels, and to evaluate the contribution of VWF secretion and clearance to the age-related changes. Methods A cross-sectional observational study was performed in a cohort of 207 normal individuals, whose levels of VWF, FVIII, VWF propeptide (VWFpp), VWFpp/VWF:Ag ratio and blood type A antigen content on VWF (A-VWF) were quantified. Results Aging and ABO blood type exerted interrelated effects on VWF and FVIII plasma levels, because the age-related increase in both proteins was significantly higher in type non-O individuals (β = 0.011 vs. 0.005). This increase with age in non-O subjects drove the differences between blood types in VWF levels, as the mean difference increased from 0.13 U/mL in the young to 0.57 U/mL in the old. Moreover, A-VWF was associated with both VWF antigen (β = 0.29; 95% confidence interval [CI], 0.09, 0.50) and VWF clearance (β = -0.15; 95% CI, -0.25, -0.06). We also documented an effect of ABO blood type on VWF secretion with aging, as old individuals with blood type non-O showed higher levels of VWFpp (mean difference 0.29 U/mL). Conclusions Aging and ABO blood type have an interrelated effect on VWF and FVIII levels, where the effect of one is significantly influenced by the presence of the other.
UNLABELLED: Essentials von Willebrand factor (VWF) and factor VIII (FVIII) levels are modulated by age and ABO status. The effect of aging and ABO blood type on VWF and FVIII was assessed in 207 normal individuals. Aging and ABO blood type showed combined and bidirectional influences on VWF and FVIII levels. Aging and ABO blood type influence VWF levels through both secretion and clearance mechanisms. SUMMARY: Background The effect of aging and ABO blood type on plasma levels of von Willebrand factor (VWF) and factor VIII (FVIII) have been widely reported; however, a comprehensive analysis of their combined effect has not been performed and the mechanisms responsible for the age-related changes have not been determined. Objectives To assess the influence of aging and ABO blood type on VWF and FVIII levels, and to evaluate the contribution of VWF secretion and clearance to the age-related changes. Methods A cross-sectional observational study was performed in a cohort of 207 normal individuals, whose levels of VWF, FVIII, VWFpropeptide (VWFpp), VWFpp/VWF:Ag ratio and blood type A antigen content on VWF (A-VWF) were quantified. Results Aging and ABO blood type exerted interrelated effects on VWF and FVIII plasma levels, because the age-related increase in both proteins was significantly higher in type non-O individuals (β = 0.011 vs. 0.005). This increase with age in non-O subjects drove the differences between blood types in VWF levels, as the mean difference increased from 0.13 U/mL in the young to 0.57 U/mL in the old. Moreover, A-VWF was associated with both VWF antigen (β = 0.29; 95% confidence interval [CI], 0.09, 0.50) and VWF clearance (β = -0.15; 95% CI, -0.25, -0.06). We also documented an effect of ABO blood type on VWF secretion with aging, as old individuals with blood type non-O showed higher levels of VWFpp (mean difference 0.29 U/mL). Conclusions Aging and ABO blood type have an interrelated effect on VWF and FVIII levels, where the effect of one is significantly influenced by the presence of the other.
Authors: Emmanuel J Favaloro; Soma Soltani; Jane McDonald; Ella Grezchnik; Leanne Easton; James W C Favaloro Journal: Am J Clin Pathol Date: 2005-12 Impact factor: 2.493
Authors: Y V Sanders; M A Giezenaar; B A P Laros-van Gorkom; K Meijer; J G van der Bom; M H Cnossen; M R Nijziel; P F Ypma; K Fijnvandraat; J Eikenboom; E P Mauser-Bunschoten; F W G Leebeek Journal: J Thromb Haemost Date: 2014-07 Impact factor: 5.824
Authors: A Y Nossent; V VAN Marion; N H VAN Tilburg; F R Rosendaal; R M Bertina; J A VAN Mourik; H C J Eikenboom Journal: J Thromb Haemost Date: 2006-10-16 Impact factor: 5.824
Authors: Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery Journal: Blood Date: 2008-03-14 Impact factor: 22.113
Authors: Nicholas L Smith; Ming-Huei Chen; Abbas Dehghan; David P Strachan; Saonli Basu; Nicole Soranzo; Caroline Hayward; Igor Rudan; Maria Sabater-Lleal; Joshua C Bis; Moniek P M de Maat; Ann Rumley; Xiaoxiao Kong; Qiong Yang; Frances M K Williams; Veronique Vitart; Harry Campbell; Anders Mälarstig; Kerri L Wiggins; Cornelia M Van Duijn; Wendy L McArdle; James S Pankow; Andrew D Johnson; Angela Silveira; Barbara McKnight; Andre G Uitterlinden; Nena Aleksic; James B Meigs; Annette Peters; Wolfgang Koenig; Mary Cushman; Sekar Kathiresan; Jerome I Rotter; Edwin G Bovill; Albert Hofman; Eric Boerwinkle; Geoffrey H Tofler; John F Peden; Bruce M Psaty; Frank Leebeek; Aaron R Folsom; Martin G Larson; Timothy D Spector; Alan F Wright; James F Wilson; Anders Hamsten; Thomas Lumley; Jacqueline C M Witteman; Weihong Tang; Christopher J O'Donnell Journal: Circulation Date: 2010-03-15 Impact factor: 29.690
Authors: Ahmad H Mufti; Kenichi Ogiwara; Laura L Swystun; Jeroen C J Eikenboom; Ulrich Budde; Wilma M Hopman; Christer Halldén; Jenny Goudemand; Ian R Peake; Anne C Goodeve; David Lillicrap; Daniel J Hampshire Journal: Blood Adv Date: 2018-07-10
Authors: Victoria Candy; Hilary Whitworth; Julie Grabell; Lisa Thibeault; Lori Harpell; Mackenzie Bowman; David Good; Wilma M Hopman; Robert F Sidonio; Paula D James Journal: Blood Adv Date: 2018-10-23
Authors: M L Bowman; F G Pluthero; A Tuttle; L Casey; L Li; H Christensen; K S Robinson; D Lillicrap; W H A Kahr; P James Journal: J Thromb Haemost Date: 2017-06-06 Impact factor: 5.824
Authors: Laura M Raffield; Ake T Lu; Mindy D Szeto; Amarise Little; Kelsey E Grinde; Jessica Shaw; Paul L Auer; Mary Cushman; Steve Horvath; Marguerite R Irvin; Ethan M Lange; Leslie A Lange; Deborah A Nickerson; Timothy A Thornton; James G Wilson; Marsha M Wheeler; Neil A Zakai; Alex P Reiner Journal: J Thromb Haemost Date: 2020-02-20 Impact factor: 5.824
Authors: Liuyang Wang; Thomas J Balmat; Alejandro L Antonia; Florica J Constantine; Ricardo Henao; Thomas W Burke; Andy Ingham; Micah T McClain; Ephraim L Tsalik; Emily R Ko; Geoffrey S Ginsburg; Mark R DeLong; Xiling Shen; Christopher W Woods; Elizabeth R Hauser; Dennis C Ko Journal: Genome Med Date: 2021-05-17 Impact factor: 15.266